Shoulder Injury Related to Vaccine Administration (SIRVA)

Brandon C. Taylor, MD; David Hinke, MD


Appl Radiol. 2014;43(12):30-31. 

In This Article


Shoulder injury related to vaccine administration (SIRVA) is a sequela of the body's immune response to direct intracapsular inoculation. Given the available literature on SIRVA, our patient's presentation fits well within the described typical history and symptomatology—absence of prior shoulder dysfunction, rapid onset of pain, and limited range of motion.[1] Assuming compliance with the current Centers for Disease Control and Prevention (CDC) vaccine administration protocol for a woman weighing less than 70 kg (our patient weighed 63 kg with a BMI of 22), a 1-inch needle was used for our patient's injection. Using MR and CT to measure the deltoid fat pad and muscle thickness, Lippert and Wall studied the rate of over-penetration using the CDC-recommended needle lengths in pediatric patients of varying weights and BMI's ranging in 3–18 years of age. They reported a risk ranging from 11–61% using the needle lengths recommended for each age group. Corroborating with Bodor and Montalvo's sonographic deltoid study, which reported that the sub-deltoid bursa extends 3.0 to 6.0 cm (1.18 – 2.38 in) laterally beyond the acromion border and is 0.8 to 1.6 cm deep to the skin surface, Lippert and Wall made a weight-based recommendation that a ½ needle length should be used in any female weighing less than 70 kg, avoiding the top third of the deltoid to ensure a 0% risk of over penetration.[2,3,6]

Careful study of our patient's chart noted that her symptoms began to improve, albeit minimally, around 6 weeks. This corresponds to a rabbit study by Dumonde demonstrating that antigen injected within synovial tissues was bound to existing antibody within the synovial tissues which resulted in a prolonged immune response lasting 6 weeks. As with most Americans of our patient's age, she has received prior Tdap and influenza vaccinations. With that said, our patient's prolonged response (in comparison to relatively brief discomfort resulting from a truly intramuscular injection) is likely due in part to preformed antibody existing within her synovial tissue from prior vaccinations.[1,4,5]

The humeral greater tuberosity erosion depicted on our patient's follow-up MRI reflects not only sequela of prolonged immune response, but it also strongly suggests direct needle impact—likely secondary to the CDC-recommended needle length given our patient's weight. One of the 13 patients in the 2010 case series by Atanasoff et al underwent arthroscopic shoulder repair during which the surgeons explored the deltoid needle trajectory (as identified by the patient). The needle path revealed inflamed and scarred bursa and thickened tissue around a damaged tendon. In addition, the path led to abnormally friable bone on the humeral greater tuberosity, which was noted to give way with pressure from the surgeon's needle. Our patient did not undergo surgical repair, but her MR findings are strikingly suggestive of similar pathogenesis.

In addition to the persistent physical discomfort, diagnosing and managing SIRVA can be expensive. An uncomplicated flu shot is often free of charge; however, our patient's initial "free" flu shot resulted in more than $18,000 of healthcare charges, not including the follow-up MRI and office appointments with her orthopedic surgeon. Fortunately, our patient has insurance and had to only pay about 20% of the cost out-of-pocket, unlike thousands of uninsured Americans receiving yearly vaccinations at local pharmacies and clinics nationwide.